As of June 21, 2025, Moleculin Biotech Inc (MBRX) reports a ROA (Return on Assets) of -128.58%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Moleculin Biotech Inc's ROA (Return on Assets)
Over recent years, Moleculin Biotech Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -128.58% |
| 2023-12-31 | -77.89% |
| 2022-12-31 | -50.55% |
| 2021-12-31 | -18.90% |
| 2020-12-31 | -59.78% |
This slight downward trend highlights how Moleculin Biotech Inc manages its efficiency in using assets to generate earnings over time.
Comparing Moleculin Biotech Inc's ROA (Return on Assets) to Peers
To better understand Moleculin Biotech Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Moleculin Biotech Inc (MBRX) | -128.58% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| Amgen Inc (AMGN) | 4.45% |
| Abbvie Inc (ABBV) | 3.17% |
| Liminal BioSciences Inc (LMNL) | 0.99% |
| Gilead Sciences Inc (GILD) | 0.81% |
Compared to its competitors, Moleculin Biotech Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.